Skip to main content
. Author manuscript; available in PMC: 2016 Oct 21.
Published in final edited form as: J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):314–321. doi: 10.1097/QAI.0000000000000432

TABLE 3.

Cumulative Incidence of Reaching ART Eligibility, LTF, Mortality and ART Initiation by Enrollment Eligibility Group Among Adult Patients Enrolled in Care at 41 Rwandan Health Facilities (N = 31,033)

Enrollment Eligibility Groups
Eligible Ineligible Indeterminate
Period between enrollment and reaching ART eligibility
 LTF: 6 mo N/A 7.2% (6.8 to 7.7) 11.7% (10.9 to 12.4)
 LTF: 12 mo N/A 10.1% (9.5 to 10.6) 13.8% (13.0 to 14.6)
 Mortality: 6 mo N/A 0.6% (0.5 to 0.8) 2.2% (1.9 to 2.6)
 Mortality: 12 mo N/A 1.2% (1.0 to 1.4) 3.2% (2.8 to 3.6)
 Reached ART eligibility: 6 mo N/A 8.0% (7.6 to 8.5) 12.9% (12.1 to 13.7)
 Reached ART eligibility: 12 mo N/A 17.9% (17.2 to 18.6) 22.8% (21.7 to 23.8)
Period between ART eligibility and ART initiation
 LTF: 6 mo 2.7% (2.4 to 3.1) 1.5% (1.2 to 1.9) 1.5% (1.1 to 2.1)
 LTF: 12 mo 3.1% (2.7 to 3.4) 2.1% (1.7 to 2.6) 2.2% (1.6 to 2.8)
 Mortality: 6 mo 2.8% (2.5 to 3.2) 0.6% (0.4 to 1.0) 1.3% (0.9 to 1.8)
 Mortality: 12 mo 3.3% (2.9 to 3.6) 0.7% (0.5 to 1.0) 1.5% (1.0 to 2.1)
 Initiated ART: 1 mo (30 days) 53.0% (52.0 to 54.0) 41.5% (40.0 to 43.0) 40.8% (38.8 to 42.7)
 Initiated ART: 3 months (90 days) 77.2% (76.4 to 78.0) 67.9% (66.4 to 69.3) 63.8% (61.9 to 65.8)
 Initiated ART: 6 months (180 days) 83.2% (82.4 to 83.9) 77.2% (75.8 to 78.5) 74.0% (72.0 to 75.7)
 Initiated ART: 12 months (365 days) 87.6% (86.9 to 88.2) 85.5% (84.3 to 86.5) 83.7% (82.0 to 85.1)

All values are represented as cumulative incidence (95% CI).